Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 18
Submit an article Journal homepage
310
Views
21
CrossRef citations to date
0
Altmetric
Drug Evaluations

Pazopanib: therapeutic developments

Suwicha Limvorasak University of Chicago, Department of Pharmaceutical Services, 5841 S. Maryland Avenue, MC2115, Chicago, IL 60637, USA +1 773 834 5137; +1 773 702 3163
&
Edwin M Posadas University of Chicago, Department of Medicine, Hematology and Oncology, 5841 S. Maryland Avenue, MC2115, Chicago, IL 60637, USA [email protected]
, MD
Pages 3091-3102 | Published online: 02 Dec 2009

Bibliography

  • Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76
  • Duda DG, Batchelor TT, Willett CG, VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 2007;13:223-30
  • O'Reilly MS. Antiangiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer. Int J Radiat Oncol Biol Phys 2007;69:S64-6
  • Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25
  • Presta LG, Chen H, O'Connor SJ, Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9
  • Borgstrom P, Hillan KJ, Sriramarao P, Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996;56:4032-9
  • Morabito A, De Maio E, Di Maio M, Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006;11:753-64
  • Kumar R, Knick VB, Rudolph SK, Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6:2012-21
  • Hartman GD, Fraley ME, Bilodeau MT. Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents. Expert Opin Investig Drugs 2002;11:737-45
  • Sloan B, Scheinfeld NS. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs 2008;9:1324-35
  • Cao Y, Liu Q. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis. Adv Cancer Res 2007;97:203-24
  • Cao Y, Zhong W. Tumor-derived lymphangiogenic factors and lymphatic metastasis. Biomed Pharmacother 2007;61:534-9
  • Harris PA, Boloor A, Cheung M, Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-m ethyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 2008;51:4632-40
  • Liu DQ, Chen TK, McGuire MA, Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process. J Pharm Biomed Anal 2009;50:144-50
  • Sorbera L, Bolos J, Serradell N. Pazopanib hydrochloride. Oncolytic, agiogenesis inhibitor, VEGFR-2 tyrosine kinase inhibitor. Drugs Future 2006;31:585-9
  • Sonpavde G, Hutson TE, Sternberg CN. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin Investig Drugs 2008;17:253-61
  • Dev IK, Dornsife RE, Hopper TM, Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models. Br J Cancer 2004;91:1391-8
  • Suttle AB, Hurwitz H, Dowlati A, Pharmacokinetics (PK) and tolerability og GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. J Clin Oncol 2004;22(Suppl):Abstract 3054
  • Suttle B, Jones S, Dowlati A, Phase I study of the safety and pharmacokinetics (PK) of paclitaxel or paclitaxel with carboplatin administered in combination with pazopanib (GW786034). J Clin Oncol 2007;25(Suppl): Abstract 14118
  • Podar K, Tonon G, Sattler M, The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci USA 2006;103:19478-83
  • Hurwitz H, Dowlati A, Savage S, Safety, tolerability and pharmacokinetics of oral administration of GW786034 in patients with solid tumors. J Clin Oncol 2005;23(Suppl):Abstract 3012
  • Hurwitz HI, Dowlati A, Saini S, Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15:4220-7
  • Yau CC, Chen PJ, Curtis CM, A phase I study of pazopanib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2009;27(Suppl):Abstract 3561
  • Okita NT, Yamada Y, Takahari D, Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer. Jpn J Clin Oncol 2009;39(9):595-600
  • Brady J, Middleton M, Midgley RS, A phase I study of pazopanib in combination with FOLFOX6 or capeOx in subjects with colorectal cancer. J Clin Oncol 2009;27(Suppl):Abstract 4133
  • Pander J, Gelderblom H, Guchelaar HJ. Pharmacogenetics of EGFR and VEGF inhibition. Drug Discov Today 2007;12:1054-60
  • Pennell NA, Lynch TJ Jr. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 2009;14:399-411
  • Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007;5:203-20
  • Dejonge M, Savage S, Verweij J, A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently. J Clin Oncol 2006;24(Suppl):Abstract 3088
  • Frentzas SN, Groves MD, Barriuso J, Pazopanib and lapatinib in patients with relapsed malignant glioma: results of a phase I/II study. J Clin Oncol 2009;27(Suppl):Abstract 2040
  • Konecny GE, Meng YG, Untch M, Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004;10:1706-16
  • Taylor SK, Chia S, Dent S, A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: results after completion of stage I: a trial of the Princess Margaret hospital phase II consortium. J Clin Oncol 2009;27(Suppl): Abstract 1133
  • Slamon DJ, Gomez HL, Kabbinavar FF. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. J Clin Oncol 2008;26(Suppl):Abstract 1016
  • Stefanou D, Goussia AC, Arkoumani E, Expression of vascular endothelial growth factor and the adhesion molecule E-cadherin in non-small cell lung cancer. Anticancer Res 2003;23:4715-20
  • Ludovini V, Gregorc V, Pistola L, Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2004;46:77-85
  • Tomita M, Matsuzaki Y, Shimizu T, Vascular endothelial growth factor expression in pN2 non-small cell lung cancer: lack of prognostic value. Respirology 2005;10:31-5
  • Kajita T, Ohta Y, Kimura K, The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer 2001;85:255-60
  • Mineo TC, Ambrogi V, Baldi A, Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol 2004;57:591-7
  • Altorki N, Guarino M, Lee P, Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): a proof-of-concept phase II study. J Clin Oncol 2008;26(Suppl): Abstract 7557
  • Sleijfer S, Ray-Coquard I, Papai Z, Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009;27:3126-32
  • Sleijfer S, Papai Z, Le Cesne A. Phase II study of pazopanib (GW786034) in patients with relapsed or refractory soft tissue sarcoma (STS): EORTC 62043. J Clin Oncol 2007;25(Suppl):Abstract 10031
  • Posadas EM, Dahut WL. Angiogenesis and angiogenesis inhibitors: applications in adenocarcinoma of the prostate. In: Ross JS, Foster CS, editors, Molecular oncology of prostate cancer. 1st edition. Jones and Bartlett, Liverpool, England; 2006
  • Chi KN, Ellard SL, Hotte SJ, A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 2008;19:746-51
  • Dahut WL, Scripture C, Posadas E, A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008;14:209-14
  • Dror Michaelson M, Regan MM, Oh WK, Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009;20:913-20
  • Steinbild S, Mross K, Frost A, A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 2007;97:1480-5
  • Cox MC, Dahut WL, Figg WD. The use of thalidomide in androgen-independent prostate cancer. Urol Oncol 2006;24:246-9
  • Friedlander M, Hancock KC, Benigno B, Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: initial results of a phase II study. J Clin Oncol 2007;25(Suppl):Abstract 5561
  • Hutson TE, Bukowski RM. A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. Clin Genitourin Cancer 2006;4:296-8
  • Vakkalanka BK, Rini BI. Targeted therapy in renal cell carcinoma. Curr Opin Urol 2008;18:481-7
  • Dietrich J, Norden AD, Wen PY. Emerging antiangiogenic treatments for gliomas – efficacy and safety issues. Curr Opin Neurol 2008;21:736-44
  • Norden AD, Drappatz J, Wen PY. Antiangiogenic therapy in malignant gliomas. Curr Opin Oncol 2008;20:652-61
  • Davids M, Charlton A, Ng SS, Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic merkel cell carcinoma. J Clin Oncol 2009;27:97-100
  • Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs 2008;68:1029-36
  • Takahashi K, Saishin Y, King AG, Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol 2009;127:494-9
  • Podar K, Tonon G, Abtahi D, In vitro and in vivo activity of the VEGF receptor inhibitor pazopanib (GW786034) in multiple myeloma: therapeutic implications. Proc Am Assoc Cancer Res 2006;47: Abstract 5658
  • Podar K, Catley LP, Tai YT, GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood 2004;103:3474-9
  • Prince HM, Honemann D, Spencer A, Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). Blood 2009;113:4819-20
  • Hideshima T, Chauhan D, Podar K, Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001;28:607-12
  • Bible KC, Smallridge RC, Maples WJ, Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers. J Clin Oncol 2009;27(Suppl): Abstract 3521
  • Sternberg CN, Szczylik C, Lee E, A randomized, double-blind phase III study of pazopanib in treatment naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2009;27(Suppl): Abstract 5021
  • Bhargava P. VEGF kinase inhibitors: how do they cause hypertension? Am J Physiol Regul Integr Comp Physiol 2009;297:R1-5
  • Facemire CS, Nixon AB, Griffiths R, Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009;54:652-8
  • Rosenbaum SE, Wu S, Newman MA, Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008;16:557-66
  • Azad NS, Aragon-Ching JB, Dahut WL, Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009;15:1411-16
  • Robert C, Spatz A, Faivre S, Tyrosine kinase inhibition and grey hair. Lancet 2003;361:1056
  • Routhouska S, Gilliam AC, Mirmirani P. Hair depigmentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitor. Arch Dermatol 2006;142:1477-9
  • Widakowich C, de Castro G Jr, de Azambuja E, Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007;12:1443-55
  • Robert C, Soria JC, Spatz A, Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500
  • Botchkareva NV, Khlgatian M, Longley BJ, SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit. FASEB J 2001;15:645-58
  • Ryan CW, Von Mehren M, Rankin CJ, Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. J Clin Oncol 2008;26(Suppl):Abstract 10532
  • Keohan ML, Morgan JA, D'Adamo DR, Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: results of a phase II trial. J Clin Oncol 2008;26(Suppl):Abstract 10533
  • Matei D, Sill MW, Degeest K, Bristow RE. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a gynecologic oncology group (GOG) study. J Clin Oncol 2008;26(Suppl):Abstract 5537
  • Biagi JJ, Oza AM, Grimshaw R, A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma – NCIC CTG IND 185. J Clin Oncol 2008;26(Suppl):Abstract 5522
  • Deprimo SE, Friece C, Smeraglia J, Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT patients with metastatic breast cancer. ASCO Annual Meeting Proceedings Part 1. J Clin Oncol 2006;24(18S):578
  • Aspitia AM, Morton RF, Hillman DW, Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracycline or taxanes: North central cancer treatment group and Mayo Clinic trial N0336. J Clin Oncol 2009;27:11-15

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.